Sonoma Pharmaceuticals Inc./$SNOA
1D1W1MYTD1Y5YMAX
Capital at risk
About Sonoma Pharmaceuticals Inc.
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.
- Ticker
- $SNOA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 10
- Headquarters
- Boulder, United States
- Website
- sonomapharma.com
SNOA Metrics
BasicAdvanced
$6M
-
-$1.01
1.29
-
Price and volume
Market cap
$6M
Beta
1.29
52-week high
$4.60
52-week low
$0.85
Average daily volume
174K
Financial strength
Current ratio
2.987
Quick ratio
1.564
Long term debt to equity
0.067
Total debt to equity
0.112
Profitability
EBITDA (TTM)
-1.271
Gross margin (TTM)
38.91%
Net profit margin (TTM)
-10.33%
Operating margin (TTM)
-6.41%
Effective tax rate (TTM)
9.69%
Revenue per employee (TTM)
$2,190,000
Management effectiveness
Return on assets (TTM)
-5.37%
Return on equity (TTM)
-42.52%
Valuation
Price to revenue (TTM)
0.128
Price to book
0.91
Price to tangible book (TTM)
0.91
Price to free cash flow (TTM)
-1.061
Free cash flow yield (TTM)
-94.27%
Free cash flow per share (TTM)
-1.188
Growth
Revenue change (TTM)
47.00%
Earnings per share change (TTM)
-59.02%
3-year revenue growth (CAGR)
19.90%
10-year revenue growth (CAGR)
10.16%
3-year earnings per share growth (CAGR)
-67.50%
10-year earnings per share growth (CAGR)
-46.45%
Upcoming events
No upcoming events
SNOA News
AllArticlesVideos
Sonoma Pharmaceuticals Delivers 141% U.S. Revenue Growth in FY Q1, 60% Total Revenue Growth and First-Ever Positive Adjusted EBITDA
Accesswire1 month ago
Sonoma Pharmaceuticals Turns EBITDA Positive for First Time with Record Quarterly Revenue
Benzinga1 month ago
Sonoma Pharmaceuticals Receives FDA 510(k) Clearance Expanding Indications and Packaging Options for Microdacyn(R) Wound Irrigation Solution
Accesswire3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.